Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15577790 | 0.76 | PRKCI (0.44) | NOS1METAP2CSNK2A1DYRK1AMAPK1 | |
| SCHEMBL29735151 | 0.75 | METAP2 (0.56) | NOS1METAP2CSNK2A1DYRK1AFLT3 | |
| SCHEMBL396016 | 0.75 | METAP2 (0.56) | NOS1METAP2CSNK2A1DYRK1AFLT3 | |
| SCHEMBL5569363 | 0.74 | MAPK1 (0.55) | MKNK1MAPK1XDHRETPI4KA | |
| SCHEMBL28778104 | 0.72 | PTGES (0.45) | — | |
| SCHEMBL10329 | 0.71 | DYRK1A (0.50) | NOS1METAP2CSNK2A1DYRK1AMKNK1 | |
| SCHEMBL15577539 | 0.71 | CSNK2A1 (0.39) | NOS1METAP2CSNK2A1DYRK1AMAPK1 | |
| SCHEMBL2486697 | 0.71 | CHEK2 (0.44) | NOS1METAP2CSNK2A1DYRK1AMKNK1 | |
| SCHEMBL28048087 | 0.71 | CHEK1 (0.44) | FLT3LMNATSHRSMN1; SMN2 | |
| SCHEMBL30907233 | 0.70 | XDH (0.43) | NOS1DYRK1AMKNK1MAPK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257676-A1 | Aminoisoquinoline Derivatives as Protein Kinase Inhibitors | Eternity Bioscience Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257676-A1 | Aminoisoquinoline Derivatives as Protein Kinase Inhibitors | Eternity Bioscience Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257676-A1 | Aminoisoquinoline Derivatives as Protein Kinase Inhibitors | Eternity Bioscience Inc. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-2895166-A1 | AMINOISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043296-A1 | AMINOISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2014043296-A1 | AMINOISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257676-A1 | Aminoisoquinoline Derivatives as Protein Kinase Inhibitors | BRAF, RAF1, ARAF | NOS1 3119/4885METAP2 2613/4885CSNK2A1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.